Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers

Neuroinflammation (microglial activation) and subclinical nigrostriatal dysfunction have been reported in subjects at risk of Parkinsonism. Eight non-manifesting carriers (NMCs) of LRRK2 G2019S mutation had (11)C-PK11195 and (18)F-DOPA PET to assess microglial activation and striatal dopamine system...

Descripción completa

Detalles Bibliográficos
Autores principales: Gersel Stokholm, Morten, Garrido, Alicia, Tolosa, Eduardo, Serradell, Mónica, Iranzo, Alex, Østergaard, Karen, Borghammer, Per, Møller, Arne, Parbo, Peter, Stær, Kristian, Brooks, David J., Martí, Maria José, Pavese, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359140/
https://www.ncbi.nlm.nih.gov/pubmed/32318850
http://dx.doi.org/10.1007/s00415-020-09830-3
Descripción
Sumario:Neuroinflammation (microglial activation) and subclinical nigrostriatal dysfunction have been reported in subjects at risk of Parkinsonism. Eight non-manifesting carriers (NMCs) of LRRK2 G2019S mutation had (11)C-PK11195 and (18)F-DOPA PET to assess microglial activation and striatal dopamine system integrity, respectively. Comparisons were made with healthy controls. Five LRRK2-NMCs had subclinical reductions of putaminal (18)F-DOPA uptake. Three of them had significantly raised nigral (11)C-PK11195 binding bilaterally. These findings indicate that nigrostriatal dysfunction and neuroinflammation occur in LRRK2-NMCs. Studies in larger cohorts with appropriate follow-up are needed to elucidate the significance of neuroinflammation in the premotor phase of LRRK2-PD.

Ejemplares similares